Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,582.00GBp
24 May 2019
Change (% chg)

10.40 (+0.66%)
Prev Close
1,571.60
Open
1,577.60
Day's High
1,586.80
Day's Low
1,570.60
Volume
5,536,709
Avg. Vol
7,308,432
52-wk High
1,648.80
52-wk Low
1,408.80

Latest Key Developments (Source: Significant Developments)

GSK Gets Approval Of Shingrix In China In Adults Aged 50 And Over
Thursday, 23 May 2019 

May 23 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE - GSK ANNOUNCES APPROVAL OF SHINGRIX IN CHINA FOR PREVENTION OF SHINGLES IN ADULTS AGED 50 AND OVER.GLAXOSMITHKLINE - EXPECTS TO INCREASE SUPPLY OF SHINGRIX GLOBALLY AND IS INVESTING IN SIGNIFICANT CAPACITY EXPANSION.  Full Article

GSK Changes Sales Representative Incentive Programme
Thursday, 23 May 2019 

May 23 (Reuters) - GlaxoSmithKline PLC ::STATEMENT: GSK CHANGES SALES REPRESENTATIVE INCENTIVE PROGRAMME.GLAXOSMITHKLINE - ANNOUNCING CHANGES TO INCENTIVE PROGRAMME FOR SALES REPRESENTATIVES IN CERTAIN COUNTRIES.GLAXOSMITHKLINE PLC - CHANGES REFLECT GROWING SHIFT IN GSK'S PORTFOLIO TO INNOVATIVE SPECIALTY CARE PRODUCTS, INCLUDING ONCOLOGY.GSK - CHANGES TO BE MADE TO INCENTIVE PROGRAMME FOR PHARMACEUTICAL, VACCINES SALES REPRESENTATIVES TO "BETTER RECOGNISE & REWARD INDIVIDUAL EFFORT".GSK- IN SPECIALTY CARE, CAPPED VARIABLE PAY ELEMENT OF A SALES REPRESENTATIVE'S COMPENSATION WILL BE EVALUATED ON BASIS OF INDIVIDUAL SALES TARGETS.GSK - CHANGES TO INCENTIVE PROGRAMME WILL BE APPLIED INITIALLY IN US, UK AND CANADA FROM JULY 2019.  Full Article

Zymeworks And Gsk Expand 2016 Azymetric Bispecific Agreement
Thursday, 16 May 2019 

May 16 (Reuters) - Zymeworks Inc::ZYMEWORKS AND GSK EXPAND 2016 AZYMETRIC™ BISPECIFIC AGREEMENT.ZYMEWORKS INC - IF ALL SIX PROGRAMS ARE DEVELOPED AND COMMERCIALIZED, THE NEW POTENTIAL VALUE OF THE COLLABORATION WOULD BE UP TO US$1.1 BILLION..ZYMEWORKS INC - ZYMEWORKS IS ELIGIBLE TO RECEIVE INCREASED TIERED ROYALTIES ON WORLDWIDE SALES.ZYMEWORKS INC - ZYMEWORKS IS ELIGIBLE TO RECEIVE INCREASED TIERED ROYALTIES ON WORLDWIDE SALES..ZYMEWORKS INC - GSK WILL NOW HAVE OPTION TO DEVELOP AND COMMERCIALIZE BISPECIFIC DRUGS ACROSS DIFFERENT DISEASE AREAS.ZYMEWORKS INC - GSK WILL HAVE ACCESS TO ZYMEWORKS’ HEAVY-LIGHT CHAIN PAIRING TECHNOLOGY, PART OF ITS PROPRIETARY AZYMETRIC PLATFORM.ZYMEWORKS INC - ZYMEWORKS WILL NOW BE ELIGIBLE TO RECEIVE INCREASED PRECLINICAL, DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS..  Full Article

Thermo Fisher Scientific To Buy Irish Manufacturing Site From GSK
Thursday, 16 May 2019 

May 16 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC TO ACQUIRE MANUFACTURING SITE IN CORK, IRELAND, FROM GSK.THERMO FISHER SCIENTIFIC INC - HAS ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE A DRUG SUBSTANCE MANUFACTURING SITE IN CORK.THERMO FISHER SCIENTIFIC INC - DEAL WITH GLAXOSMITHKLINE PLC FOR APPROXIMATELY EUR 90 MILLION IN CASH.THERMO FISHER SCIENTIFIC INC - CORK SITE WILL EXPAND CAPACITY TO MEET CUSTOMER DEMAND FOR DEVELOPMENT AND COMMERCIAL MANUFACTURING OF COMPLEX APIS.  Full Article

Australian competition regulator Not To Oppose GSK's Proposed Acquisition Of Pfizer's Consumer Healthcare Business In Australia
Thursday, 9 May 2019 

May 9 (Reuters) - Australian Competition and Consumer Commission::WILL NOT OPPOSE GSK’S PROPOSED ACQUISITION OF PFIZER’S CONSUMER HEALTHCARE BUSINESS IN AUSTRALIA.ACCC CONSIDERS THAT TRANSACTION WILL NOT SUBSTANTIALLY LESSEN COMPETITION IN ANY MARKET IN AUSTRALIA.  Full Article

Crown Laboratories Acquires Keri From GlaxoSmithKline
Wednesday, 1 May 2019 

May 1 (Reuters) - CROWN LABORATORIES ::CROWN LABORATORIES ACQUIRES KERI FROM GLAXOSMITHKLINE AND RECEIVES AN EQUITY INVESTMENT FROM GREENSPRING ASSOCIATES.CROWN LABORATORIES - FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED.  Full Article

GSK Sees FY Shingrix Sales "Significantly" Over 1 Bln Stg
Wednesday, 1 May 2019 

May 1 (Reuters) - GlaxoSmithKline PLC ::SAYS NOW EXPECT ANNUAL SALES OF SHINGRIX TO BE "SIGNIFICANTLY" MORE THAN A BILLION IN 2019 - MEDIA CALL.SAYS "HIV MARKET REMAINS COMPETITIVE"."STILL SEE OPPORTUNITY FOR CERVARIX".IN BROADER PORTFOLIO, LOOKING FORWARD TO FILING FOR SHINGRIX IN CHINA.  Full Article

GlaxoSmithKline Posts Q1 Adj EPS 30.1 Pence
Wednesday, 1 May 2019 

May 1 (Reuters) - GlaxoSmithKline Plc ::Q1 ADJUSTED EPS ROSE 22 PERCENT TO 30.1 PENCE.Q1 SALES ROSE 6 PERCENT TO 7.7 BILLION STG.2019 GUIDANCE REAFFIRMED.QTRLY TOTAL EPS 16.8P.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FULL YEAR 2019.QTRLY TOTAL HIV SALES 1.1 BILLION STG, +7 PCT AER, +4 PCT CER, INCLUDING JULUCA SALES OF 70 MILLION STG.2019 GUIDANCE REFLECTS RECENT APPROVAL OF SUBSTITUTABLE GENERIC COMPETITOR TO ADVAIR IN US AND EXPECTED IMPACT OF TESARO ACQUISITION.QTRLY PHARMACEUTICALS TURNOVER 4,158 MILLION POUNDS VERSUS 4,009 MILLION POUNDS REPORTED A YEAR EARLIER.2019 GUIDANCE ASSUMES THAT PROPOSED CONSUMER HEALTHCARE NUTRITION DISPOSAL CLOSES BY END OF 2019.QTRLY VACCINES TURNOVER 1,522 MILLION POUNDS VERSUS 1,238 MILLION POUNDS REPORTED A YEAR EARLIER.2019 GUIDANCE ALSO ASSUMES PROPOSED CONSUMER HEALTHCARE JOINT VENTURE WITH PFIZER CLOSES DURING H2 2019.DECISION HAS BEEN MADE TO TERMINATE CLINICAL DEVELOPMENT OF STREP PNEUMONIA (NEXT GENERATION) CANDIDATE VACCINE.QTRLY CONSUMER HEALTHCARE TURNOVER 1,981 MILLION POUNDS VERSUS 1,975 MILLION POUNDS REPORTED A YEAR EARLIER.DECISION HAS BEEN MADE TO NO LONGER PURSUE CLINICAL DEVELOPMENT OF CANDIDATE UNIVERSAL FLU VACCINE."REMAINS COMMITTED TO FURTHER RESEARCH IN FLU INCLUDING PURSUING OTHER APPROACHES".IF EXCHANGE RATES HOLD AT CLOSING RATES ON 31 MARCH FOR REST OF 2019, ESTIMATED NEGATIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE AROUND 1 PCT.  Full Article

GSK Receives US Approval Of Benlysta For Intravenous Use In Children With Lupus Aged 5 Years & Above
Saturday, 27 Apr 2019 

April 26 (Reuters) - GlaxoSmithKline PLC ::GSK RECEIVES US APPROVAL OF BENLYSTA FOR INTRAVENOUS USE IN CHILDREN WITH LUPUS AGED FIVE YEARS AND ABOVE.GSK - APPROVAL EXTENDS THE CURRENT INDICATION IN THE U.S. FOR THE IV FORMULATION OF BENLYSTA IN ADULTS TO LUPUS PATIENTS AGED 5 YEARS AND OLDER.  Full Article

GSK Reviewed Presentation Of Respiratory Product Sales
Thursday, 28 Mar 2019 

March 28 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - FOLLOWING APPROVAL OF A GENERIC ALTERNATIVE TO ADVAIR IN US, GSK HAS REVIEWED PRESENTATION OF ITS RESPIRATORY PRODUCT SALES.GLAXOSMITHKLINE PLC - WILL REPORT ELLIPTA PRODUCTS PORTFOLIO AND NUCALA UNDER "RESPIRATORY" CATEGORY.GLAXOSMITHKLINE PLC - WILL REPORT ALL OTHER RESPIRATORY PRODUCTS UNDER "ESTABLISHED PHARMACEUTICALS" FROM Q1.GLAXOSMITHKLINE PLC - IMPACT OF IFRS 16 FOR THE FULL YEARS 2019 AND 2020 IS EXPECTED TO BE AT A SIMILAR LEVEL TO 2018.GLAXOSMITHKLINE -CHANGE NOT EXPECTED TO AFFECT PREVIOUSLY ANNOUNCED GUIDANCE RELATED TO ITS EXPECTATIONS FOR ADJUSTED EPS GROWTH IN CER TERMS FOR 2019.GLAXOSMITHKLINE -CHANGE NOT EXPECTED TO AFFECT GROUP'S MEDIUM-TERM OUTLOOK FOR ADJUSTED EPS GROWTH IN CER TERMS FOR FIVE YEAR PERIOD 2016-2020.  Full Article

UPDATE 1-GSK brings back bonuses for some sales reps

May 23 British drugmaker GlaxoSmithKline said on Thursday it will reintroduce incentive payments for sales representatives in some countries to retain talent after stopping them for years in the wake of scandals over illegal sales practices.